<DOC>
	<DOCNO>NCT01512004</DOCNO>
	<brief_summary>The purpose Phase III study evaluate efficacy safety Propiverine Hydrochloride Extended-Release Capsule treatment overactive bladder Chinese population urgent micturition , frequent micturition and/or urge urinary incontinence .</brief_summary>
	<brief_title>Propiverine Hydrochloride Extended-Release Capsule Overactive Bladder</brief_title>
	<detailed_description>This multi-center , randomize , doubled-blind , double dummy clinical study , comparison Tolterodine Tartrate Extended-Release Tablet active parallel control evaluate efficacy safety Propiverine Hydrochloride Extended-Release Capsule treatment Overactive Bladder Chinese population urgent micturition , frequent micturition and/or urge urinary incontinence .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Aged 18 65 , male female patient diagnosis overactive bladder symptom OAB &gt; 3 month subject urinary frequency ( average micturition frequency within 24h &gt; 8 time ) , urgency and/or urge incontinence micturition diary card screen period Mean volume single micturition less 200ml micturition diary dard screen period The subject willing able complete micturition diary card correctly Subject 's urine routine test show he/she urinary tract infection Subject sign inform consent form Confirmed investigator subject severe stress incontinence . Subject serious heart disease arrhythmia , investigator 's opinion , suitable enroll . Subject contraindication anticholinergic therapy , urinary retention , gastric retention uncontrollable angle closure glaucoma . Subject symptomatic acute urinary tract infection . Subject recurrent urinary tract infection . Subject interstitial cystitis . Subject agnogenic hematuria . Subject bladder outlet obstruction clinical significance . Subject need retention catheterization intermittent catheterization . Patient malignant tumor . Subject receive anticholinergic drug drug treat OAB within washout period , receive drug study begin . Subject pregnant lactating , plan pregnant subject receive clinical study drug participate clinical trial within 30 day . Women childbearing age take sufficient contraception measure within 3 month random number distribution ; intend stop contraception measure trial within one month treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>urgent micturition</keyword>
	<keyword>frequent micturition</keyword>
	<keyword>urge urinary incontinence</keyword>
</DOC>